According to a recent LinkedIn post from Vaxinano, the company is highlighting a new peer‑reviewed publication in MDPI Animals describing a trivalent inactivated in ovo nanovaccine against avian colibacillosis in broilers. The post indicates this is presented as the first report of an inactivated in ovo vaccine targeting this disease and emphasizes strong immunogenicity and compatibility with commonly used live viral vaccines.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The LinkedIn post also underscores that the approach is designed to be scalable through Vaxinano’s nanovaccine platform and positioned for use in combined in ovo vaccines. It further explains that in ovo vaccination could enable protection before hatch, potentially improving early and uniform immunity while reducing handling and labor in commercial hatcheries.
From an investor perspective, the post suggests that Vaxinano is advancing a differentiated poultry vaccine platform aligned with industry needs to improve efficiency and flock health. If successfully commercialized, such technology could open revenue opportunities in the global poultry vaccine market and strengthen the company’s positioning within preventive animal health solutions.
The message also connects this work to broader efforts to address antimicrobial resistance, implying potential alignment with regulatory and funding priorities focused on reducing antibiotic use in livestock. Support from the International Development Research Centre’s InnoVet AMR 1.0 program, as mentioned in the post, may signal external validation of the project’s relevance and could facilitate further R&D partnerships or grant-based financing.
Overall, the LinkedIn post points to continuing progress in Vaxinano’s nanovaccine platform and its application in food‑animal production. While no commercialization timeline or financial metrics are provided, the scientific milestone, if followed by successful regulatory and market adoption, could enhance the company’s long‑term growth prospects in the veterinary vaccine segment.